Lexeo Therapeutics

Lexeo Therapeutics company information, Employees & Contact Information

Based in New York City, Lexeo Therapeutics is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Building on groundbreaking research from Weill Cornell Medicine and the University of California San Diego, Lexeo partners with preeminent institutions on the cutting edge of gene therapy research. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4 associated Alzheimer's disease programs, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization. For more information, please visit www.lexeotx.com.

Company Details

Employees
82
Founded
-
Address
345 Park Avenue South,
Phone
(212) 547-9879
Email
in****@****otx.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
New York, New York
Looking for a particular Lexeo Therapeutics employee's phone or email?

Lexeo Therapeutics Questions

News

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy - Sahm

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy Sahm

23% LVMI reduction at 12 months — Lexeo's LX2006 shows cardiac & neurologic improvement; FDA open to pooling - Stock Titan

23% LVMI reduction at 12 months — Lexeo's LX2006 shows cardiac & neurologic improvement; FDA open to pooling Stock Titan

Pathophysiology and Therapeutic Needs in Nonobstructive Hypertrophic Cardiomyopathy: - JACC Journals

Pathophysiology and Therapeutic Needs in Nonobstructive Hypertrophic Cardiomyopathy: JACC Journals

Lexeo Therapeutics CEO R. Nolan Townsend to Present at 43rd Annual J.P. Morgan Healthcare Conference - Quiver Quantitative

Lexeo Therapeutics CEO R. Nolan Townsend to Present at 43rd Annual J.P. Morgan Healthcare Conference Quiver Quantitative

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference - Yahoo Finance

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference Yahoo Finance

Eric Adler, M.D., Joins LEXEO as Chief Scientific Officer - citybiz

Eric Adler, M.D., Joins LEXEO as Chief Scientific Officer citybiz

Lexeo Therapeutics to Participate in Upcoming Investor Conferences - Stock Titan

Lexeo Therapeutics to Participate in Upcoming Investor Conferences Stock Titan

Top Lexeo Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant